- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.25 Å
- Oligo State
- hetero-4-4-4-mer
- Ligands
- 4 x F09: NONAN-1-OL(Non-covalent)
- 4 x 1EM: (1S)-2-HYDROXY-1-[(NONANOYLOXY)METHYL]ETHYL MYRISTATE(Non-covalent)
1EM.2: 11 residues within 4Å:- Chain C: V.59, L.61, R.64
- Chain L: L.16, S.19, Y.37, P.38, R.39, L.41, W.42, V.45
7 PLIP interactions:4 interactions with chain C, 3 interactions with chain L- Hydrophobic interactions: C:L.61, C:R.64, L:L.16, L:V.45
- Water bridges: C:R.64
- Salt bridges: C:R.64
- Hydrogen bonds: L:R.39
1EM.11: 11 residues within 4Å:- Chain F: V.59, L.61, R.64
- Chain I: L.16, S.19, Y.37, P.38, R.39, L.41, W.42, V.45
7 PLIP interactions:3 interactions with chain I, 4 interactions with chain F- Hydrophobic interactions: I:L.16, I:V.45, F:L.61, F:R.64
- Hydrogen bonds: I:R.39
- Water bridges: F:R.64
- Salt bridges: F:R.64
1EM.20: 11 residues within 4Å:- Chain C: L.16, S.19, Y.37, P.38, R.39, L.41, W.42, V.45
- Chain I: V.59, L.61, R.64
7 PLIP interactions:4 interactions with chain I, 3 interactions with chain C- Hydrophobic interactions: I:L.61, I:R.64, C:L.16, C:V.45
- Water bridges: I:R.64
- Salt bridges: I:R.64
- Hydrogen bonds: C:R.39
1EM.29: 11 residues within 4Å:- Chain F: L.16, S.19, Y.37, P.38, R.39, L.41, W.42, V.45
- Chain L: V.59, L.61, R.64
7 PLIP interactions:3 interactions with chain F, 4 interactions with chain L- Hydrophobic interactions: F:L.16, F:V.45, L:L.61, L:R.64
- Hydrogen bonds: F:R.39
- Water bridges: L:R.64
- Salt bridges: L:R.64
- 28 x K: POTASSIUM ION(Non-functional Binders)(Non-covalent)
K.3: 3 residues within 4Å:- Ligands: K.12, K.21, K.30
Ligand excluded by PLIPK.4: 11 residues within 4Å:- Chain C: T.50
- Chain F: T.50
- Chain I: T.50
- Chain L: T.50
- Ligands: K.5, K.13, K.14, K.22, K.23, K.31, K.32
Ligand excluded by PLIPK.5: 19 residues within 4Å:- Chain C: T.50, V.51
- Chain F: T.50, V.51
- Chain I: T.50, V.51
- Chain L: T.50, V.51
- Ligands: K.4, K.6, K.13, K.14, K.15, K.22, K.23, K.24, K.31, K.32, K.33
Ligand excluded by PLIPK.6: 19 residues within 4Å:- Chain C: V.51, G.52
- Chain F: V.51, G.52
- Chain I: V.51, G.52
- Chain L: V.51, G.52
- Ligands: K.5, K.7, K.14, K.15, K.16, K.23, K.24, K.25, K.32, K.33, K.34
Ligand excluded by PLIPK.7: 15 residues within 4Å:- Chain C: G.52, Y.53
- Chain F: G.52, Y.53
- Chain I: G.52, Y.53
- Chain L: G.52, Y.53
- Ligands: K.6, K.15, K.16, K.24, K.25, K.33, K.34
Ligand excluded by PLIPK.8: 7 residues within 4Å:- Ligands: K.9, K.17, K.18, K.26, K.27, K.35, K.36
Ligand excluded by PLIPK.9: 7 residues within 4Å:- Ligands: K.8, K.17, K.18, K.26, K.27, K.35, K.36
Ligand excluded by PLIPK.12: 3 residues within 4Å:- Ligands: K.3, K.21, K.30
Ligand excluded by PLIPK.13: 11 residues within 4Å:- Chain C: T.50
- Chain F: T.50
- Chain I: T.50
- Chain L: T.50
- Ligands: K.4, K.5, K.14, K.22, K.23, K.31, K.32
Ligand excluded by PLIPK.14: 19 residues within 4Å:- Chain C: T.50, V.51
- Chain F: T.50, V.51
- Chain I: T.50, V.51
- Chain L: T.50, V.51
- Ligands: K.4, K.5, K.6, K.13, K.15, K.22, K.23, K.24, K.31, K.32, K.33
Ligand excluded by PLIPK.15: 19 residues within 4Å:- Chain C: V.51, G.52
- Chain F: V.51, G.52
- Chain I: V.51, G.52
- Chain L: V.51, G.52
- Ligands: K.5, K.6, K.7, K.14, K.16, K.23, K.24, K.25, K.32, K.33, K.34
Ligand excluded by PLIPK.16: 15 residues within 4Å:- Chain C: G.52, Y.53
- Chain F: G.52, Y.53
- Chain I: G.52, Y.53
- Chain L: G.52, Y.53
- Ligands: K.6, K.7, K.15, K.24, K.25, K.33, K.34
Ligand excluded by PLIPK.17: 7 residues within 4Å:- Ligands: K.8, K.9, K.18, K.26, K.27, K.35, K.36
Ligand excluded by PLIPK.18: 7 residues within 4Å:- Ligands: K.8, K.9, K.17, K.26, K.27, K.35, K.36
Ligand excluded by PLIPK.21: 3 residues within 4Å:- Ligands: K.3, K.12, K.30
Ligand excluded by PLIPK.22: 11 residues within 4Å:- Chain C: T.50
- Chain F: T.50
- Chain I: T.50
- Chain L: T.50
- Ligands: K.4, K.5, K.13, K.14, K.23, K.31, K.32
Ligand excluded by PLIPK.23: 19 residues within 4Å:- Chain C: T.50, V.51
- Chain F: T.50, V.51
- Chain I: T.50, V.51
- Chain L: T.50, V.51
- Ligands: K.4, K.5, K.6, K.13, K.14, K.15, K.22, K.24, K.31, K.32, K.33
Ligand excluded by PLIPK.24: 19 residues within 4Å:- Chain C: V.51, G.52
- Chain F: V.51, G.52
- Chain I: V.51, G.52
- Chain L: V.51, G.52
- Ligands: K.5, K.6, K.7, K.14, K.15, K.16, K.23, K.25, K.32, K.33, K.34
Ligand excluded by PLIPK.25: 15 residues within 4Å:- Chain C: G.52, Y.53
- Chain F: G.52, Y.53
- Chain I: G.52, Y.53
- Chain L: G.52, Y.53
- Ligands: K.6, K.7, K.15, K.16, K.24, K.33, K.34
Ligand excluded by PLIPK.26: 7 residues within 4Å:- Ligands: K.8, K.9, K.17, K.18, K.27, K.35, K.36
Ligand excluded by PLIPK.27: 7 residues within 4Å:- Ligands: K.8, K.9, K.17, K.18, K.26, K.35, K.36
Ligand excluded by PLIPK.30: 3 residues within 4Å:- Ligands: K.3, K.12, K.21
Ligand excluded by PLIPK.31: 11 residues within 4Å:- Chain C: T.50
- Chain F: T.50
- Chain I: T.50
- Chain L: T.50
- Ligands: K.4, K.5, K.13, K.14, K.22, K.23, K.32
Ligand excluded by PLIPK.32: 19 residues within 4Å:- Chain C: T.50, V.51
- Chain F: T.50, V.51
- Chain I: T.50, V.51
- Chain L: T.50, V.51
- Ligands: K.4, K.5, K.6, K.13, K.14, K.15, K.22, K.23, K.24, K.31, K.33
Ligand excluded by PLIPK.33: 19 residues within 4Å:- Chain C: V.51, G.52
- Chain F: V.51, G.52
- Chain I: V.51, G.52
- Chain L: V.51, G.52
- Ligands: K.5, K.6, K.7, K.14, K.15, K.16, K.23, K.24, K.25, K.32, K.34
Ligand excluded by PLIPK.34: 15 residues within 4Å:- Chain C: G.52, Y.53
- Chain F: G.52, Y.53
- Chain I: G.52, Y.53
- Chain L: G.52, Y.53
- Ligands: K.6, K.7, K.15, K.16, K.24, K.25, K.33
Ligand excluded by PLIPK.35: 7 residues within 4Å:- Ligands: K.8, K.9, K.17, K.18, K.26, K.27, K.36
Ligand excluded by PLIPK.36: 7 residues within 4Å:- Ligands: K.8, K.9, K.17, K.18, K.26, K.27, K.35
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cuello, L.G. et al., The gating cycle of a K+ channel at atomic resolution. Elife (2017)
- Release Date
- 2017-12-06
- Peptides
- Antibody Heavy Chain: ADGJ
Antibody Light Chain: BEHK
pH-gated potassium channel KcsA: CFIL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AD
AG
AJ
AB
BE
BH
BK
BC
CF
CI
CL
C - Membrane
-
We predict this structure to be a membrane protein.
SMTL ID : 5vk6.1
Open conformation of KcsA non-inactivating E71A mutant
Antibody Heavy Chain
Toggle Identical (ADGJ)Antibody Light Chain
Toggle Identical (BEHK)pH-gated potassium channel KcsA
Toggle Identical (CFIL)Related Entries With Identical Sequence
1k4c.1 | 1k4d.1 | 1r3i.1 | 1r3j.1 | 1r3k.1 | 1r3l.1 | 1s5h.1 | 1zwi.1 | 2atk.1 | 2bob.1 | 2boc.1 | 2dwd.1 | 2dwe.1 | 2h8p.1 | 2hfe.1 | 2hg5.1 | 2hjf.1 | 2hvj.1 | 2hvk.1 | 2ih1.1 | 2ih3.1 | 2itc.1 | 2itd.1 | 2jk5.1 | 2nlj.1 | 2p7t.2 | 2p7t.3 | 2w0f.1 | 3f5w.1 | 3f7v.1 more...less...3f7v.2 | 3f7y.1 | 3f7y.2 | 3fb5.1 | 3fb5.2 | 3fb6.1 | 3fb6.2 | 3fb7.1 | 3fb7.2 | 3fb8.1 | 3fb8.2 | 3fb8.3 | 3gb7.1 | 3hpl.1 | 3iga.1 | 3ogc.1 | 3or6.1 | 3or7.1 | 3stl.1 | 3stz.1 | 4lbe.1 | 4lcu.1 | 4msw.1 | 4uuj.1 | 5e1a.1 | 5ebl.1 | 5ebm.1 | 5ec1.1 | 5ec2.1 | 5j9p.1 | 5vke.1 | 5vkh.1 | 6by2.1 | 6by3.1 | 6nfu.1 | 6nfv.1 | 6pa0.1 | 6w0a.1 | 6w0b.1 | 6w0c.1 | 6w0d.1 | 6w0e.1 | 6w0f.1 | 6w0g.1 | 6w0h.1 | 6w0i.1 | 6w0j.1 | 7m2h.1 | 7m2h.2 | 7m2i.1 | 7m2j.1 | 7mhr.1 | 7mhx.1 | 7rp0.1 | 7sqw.1